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Background: It has been shown that human immunodeficiency virus (HIV)-1 infection induces the production of
endogenous lipids required for effective viral production, and the cluster of differentiation (CD)1 molecule CD1d is
downregulated by HIV-1 infection. However, the role of endogenous lipid presentation and the implications of CD1
downregulation by HIV-1 infection have not yet been characterized.
Results: In this study, we observed downregulation of both CD1c and CD1d expression through a Vpu-dependent
and Nef-independent mechanism, and the concomitant HIV-1-induced production of host cholesterol decreased
the extent of CD1c and CD1d modulation. While the modest downregulation of CD1c by HIV-1 infection decreased
the ability of CD1c-restricted T cells to respond and secrete interferon-γ, the cholesterol upregulation in the same
cells by HIV-1 infection appears to limit the downregulation of CD1c.
Conclusions: The two conflicting HIV-1-mediated changes in CD1c expression appear to minimize the modulation
of CD1c expression, thus leading the host to maintain a CD1c-restricted T-cell response against HIV-1.
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Human immunodeficiency virus (HIV)-1, the etiological
agent of acquired immune deficiency syndrome (AIDS),
infects nearly 40 million people worldwide. Despite numer-
ous advances in the understanding of HIV/AIDS, attempts
at inducing a major histocompatibility complex (MHC)-
restricted immune response, although promising in some
respects, have failed to generate a sufficient response to
clear the infection. This could be due to the breadth of the
response, the type of response, such as responses mediated
by cytotoxic T cells versus those mediated by antibodies, or
the timing of the response, such as a response that is too
late to keep up with the high viral replication rate.
Cluster of differentiation (CD)1 molecules are non-
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reproduction in any medium, provided the orβ2-microglobulin on the surface of various types of cells,
particularly antigen-presenting cells (APCs). However,
unlike MHC molecules that present peptide antigen to
T cells, CD1 molecules have hydrophobic binding pock-
ets that bind hydrocarbon chains making them suitable
for presentation of lipid antigens [1-3]. In humans, there
are five types of CD1s: CD1 a, b, and c are classified in
group 1, CD1d in group 2 and CD1e in group 3. Group 1
CD1s and CD1d are recognized by CD1-restricted T cells
and invariant natural killer T (iNKT) cells, respectively.
CD1 molecules present both endogenous and pathogen-
derived lipids. For presentation of endogenous lipids, it is
thought that pathogen engagement of cellular proteins,
such as toll-like receptors, can induce the production of
endogenous lipids, and the subsequent increase in lipid
presentation by CD1 molecules induces the activation of
CD1-restricted T cells [2]. Several groups have inves-
tigated the reactivity of CD1-restricted cells against both
endogenous- [4-10] and pathogen- [1,7,11-15] derived
lipids. Murine CD1d-restricted T-cell hybridomas recognize
CD1d molecules presenting phosphatidylinositol, phospha-
tidylethanolamine, and phosphatidylglycerol [6]. In humans,d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 CD1c-restricted T cells are reactive against the
endogenous lipid phosphatidylcholine. HeLa cells were
transfected with CD1c and CD1d constructs and used as antigen
presenting cells. The HeLa-CD1 cells were loaded with 50 μg/ml
phosphatidylcholine (PC) and used to stimulate CD1c-restricted T
cells for 24 hours. Supernatants were collected and used in an IFN-γ
ELISA. Data represent results from one of three independent
experiments.
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sides found in melanomas have been shown to be recog-
nized by CD1d-restricted T cells [1]. Sulfatide, a lipid found
primarily in the brain, is thought to be a promiscuous lipid
and is recognized by CD1a, b, and c- restricted T cells in
humans [16]. Recently, it has been shown that CD1-
restricted T cells reactive against self lipids are bi-functional,
as they can also recognize foreign mycobacterial-derived
lipids. These cells were shown to be CD8+, have an αβ T-
cell receptor (TCR), and possess cytolytic activity [7]. The
recognition of lipids by their CD1-restricted T cells can
mediate cytokine production [4], induce maturation of den-
dritic cells (DCs) [17,18], and activate other cells in the
immune response [12,19].
Unlike proteins, lipids are relatively conserved. Thus,
the limited variability of lipids suggests that CD1-
restricted T cells could play an important role in the im-
mune response long before MHC-restricted T cells and
B cells have had a chance to expand. In line with this,
studies that assessed the effects of viral infection on
CD1 expression showed that CD1d was downregulated
during herpes infection [20,21], and the lack of CD1d
or Jα18 iNKT cells resulted in an impaired capacity to
clear the infection [22]. HIV-1 has also been shown to
downregulate CD1d expression and antigen-presentation
capabilities [23-27]. A few studies indicate that this
phenomenon is caused in part through interactions be-
tween the Nef protein and the cytoplasmic tail of the
CD1d molecule in a manner similar to the downregula-
tion of MHC-class I and CD4 molecules [23,24]. How-
ever, one study showed that Nef did not bind to or alter
the expression of molecules with the CD1d cytoplasmic
tail [26]. Another recent study showed the inhibition of
CD1d recycling from endosomal compartments to the
cell surface by interactions between Vpu and CD1d
molecules [27]. Together, these studies suggest that the
viruses downregulate the CD1 molecules in an effort to
evade or delay the immune response against the infec-
tion. However, to date, the consequences of this down-
regulation have not been studied in greater detail.
Lipid rafts are specialized membrane domains enriched
in certain lipids, cholesterol, and proteins. The HIV-1 gag
protein associates with lipid rafts to facilitate viral bud-
ding. Cholesterol plays a central role in maintaining the
function of these rafts, and the depletion of cholesterol
markedly reduces HIV-1 virion production [28]. Micro-
array analysis of infected cells has revealed that the pres-
ence of HIV-1 increases the expression of cholesterol
genes and the incorporation of cholesterol precursors, and
these effects are mediated by Nef [29,30]. These studies
suggest that endogenous lipids may play a vital role in sus-
taining the viral life cycle within the host and/or enhan-
cing viral productivity. However, it is not yet known
whether the increase in endogenous lipid productioninduced by HIV-1 infection can also result in an increase
in the presentation of these lipids by CD1 on the cell sur-
face to signal the immune system that an infection has oc-
curred. We sought to address the role of endogenous lipid
presentation during HIV-1 infection. To accomplish this,
we assessed how increased cholesterol production affects
CD1c expression and the activation of CD1c-restricted
T cells, how the modulation of CD1c expression is trig-
gered by HIV-1 infection, and how modulation of CD1c
expression by HIV-1 affects CD1c-restricted T-cell activa-
tion and consequently viral production.
Results
Characterization of CD1c-restricted T cells
To generate CD1c-restricted T cells, human T cells were
isolated from healthy donors and stimulated for several
weeks with autologous DCs loaded with the endogenous
lipid phosphatidylcholine (PC). These cells were then
tested for functionality, CD1c-restriction, and pheno-
typed. The analysis indicated that these CD8+, αβ TCR,
non-cytotoxic (data not shown) T cells are PC-reactive
and CD1c-restricted (Figure 1).
Expression levels of CD1c/CD1d molecules during
increased lipid synthesis
HIV-1 infection induces the production of cholesterol
[29,30], which may be presented by CD1c/CD1d mole-
cules to initiate an immune response. To address this
issue, we determined whether increased lipid production
results in increased CD1c/CD1d expression. To accom-
plish this, Jurkat cells were cultured for 10 days in the
presence of mevalonate, a precursor and known choles-
terol inducer. The measurement of cholesterol produc-
tion revealed that the treated cells produced significantly
more cholesterol than untreated controls (Table 1).







* p < 0.05, # p < 0.05.
Total cell cholesterol was measured in Jurkat cells untreated or treated with
200 μM mevalonate or infected with HIV IIIB using the Amplex Red Cholesterol
Kit, as described. * Indicates a significant difference between the untreated
and the mevalonate treated cells. # Indicates a significant difference between
untreated cells and HIV infected cells. Data represent results from one of three
independent experiments.
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CD1c/CD1d levels remained unchanged (Figure 2A),
suggesting that increased lipid synthesis does not result
in increased CD1c/CD1d expression.
Effects of increased cholesterol on CD1c-restricted T-cell
responses
We next wanted to know whether cells producing excess
cholesterol were more capable of inducing CD1c-
restricted T cells to secrete interferon (IFN)-γ compared
to cells not producing excess lipid. Jurkat cells were trea-
ted with 200 μM of mevalonate and used to stimulate
the secretion of IFN-γ from CD1c-restricted T cells. The
cells treated with mevalonate had an enhanced capacity
to stimulate CD1c-restricted T cells compared to un-
treated controls (Figure 2B), suggesting that CD1c-
restricted T cells may be able to recognize increased
lipid levels in the context of CD1c molecules.
Effects of HIV-1 infection on CD1c/CD1d expression
Based on our findings that an increase in cholesterol
production resulted in increased stimulation of CD1c-
restricted T cells and studies by other groups showingFigure 2 Increased cholesterol production does not alter CD1c/CD1d
cells were cultured in the presence of varying amounts of mevalonate, a p
assessed 10 days later via FACS. Data were averaged from three independe
200 μM mevalonate for 10 days and then used to stimulate CD1c-restricted
IFN-γ ELISA. Standard deviation bars are averaged from three separate expethat HIV induces cholesterol production [28,29], we next
assessed the level of CD1c expression during HIV-1 in-
fection. For this purpose, we infected Jurkat cells with
HIV-1 IIIb and measured CD1c/CD1d expression by
FACS on day 10. We found that CD1c was downregu-
lated 40% compared to uninfected controls, while CD1d
was downregulated by 53% on average from the cell sur-
face (Figure 3A). Similar levels of CD1c/CD1d modula-
tion were found with varying viral titrations, suggesting
that the viral titer does not significantly affect the levels
of CD1c and CD1d downregulation (data not shown).
Effects of Nef and Vpu on CD1c/CD1d expression
The mechanism of CD1 molecule modulation during
HIV-1 infection is poorly understood. While some have
shown that CD1d is downregulated by Nef [23,24], one
study showed that Nef does not alter the expression of
CD1d [26], and another showed that CD1d expression is
downregulated by Vpu [27]. When we infected Jurkat
cells with wild-type (WT), Nef-deleted (ΔNef) or Vpu-
deleted (ΔVpu) viruses, we found a significant difference
between the WT and ΔVpu-infected cells, but not the
WT and ΔNef infected cells on days 2 (Figure 4A) and
10 (Figure 4B) post-infection. The viral RNA copy num-
bers among different viruses were similar (Figure 4C). In
fact, the viral load of ΔVpu virus appeared to be slightly
higher than that of ΔNef virus (Figure 4C), ensuring that
the CD1 down-modulation was not due to the amounts
of viruses used to infect Jurkat cells.
In order to confirm whether Vpu itself is sufficient to
accomplish this function, we transfected Jurkat cells with
a Vpu-expressing plasmid and determined the expression
of CD1c/CD1d molecules by the transfected Jurkat cells.
As shown in Figure 5, the transfection of a plasmid encod-
ing only Vpu could significantly downregulated both
CD1c and CD1d albeit to a lesser degree than that caused
by WT plasmid encoding a whole HIV-1 sequence.expression, but induces IFN-γ in CD1c-restricted T cells. (A) Jurkat
recursor and inducer of cholesterol. CD1c and CD1d expression was
nt experiments. (B) Jurkat cells were either untreated or cultured with
T cells for 24 hours. Supernatants were collected and analyzed by
riments.
Figure 3 Effects of HIV-1 on CD1c/CD1d expression. (A) HIV-1
infection modulates CD1c/CD1d expression. Jurkat cells were mock
or HIV-1 IIIb infected for 10 days, and the levels of CD1c and CD1d
expression were measured by FACS. CD1c/CD1d expression was
normalized using uninfected, treated controls and plotted as %
modulation from the controls. (B) Blocking cholesterol production
results in significant CD1c/CD1d downregulation during HIV-1
infection. Jurkat cells were either treated with simvastatin, an
inhibitor of cholesterol synthesis, or infected with HIV IIIb and
cultured for 5 days. The levels of CD1c and CD1d expression were
assessed by FACS, and data were normalized using uninfected,
treated controls and plotted as % modulation from controls. All data
represent results from one of three independent experiments.
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CD1c and CD1d expression were downregulated in a
Vpu-dependent and Nef-independent fashion.
The effect of HIV-1-induced cholesterol synthesis on
CD1 expression
The measurement of cholesterol production in the HIV-
1-infected cells showed a significant 2-fold increase in
cholesterol production compared to uninfected controls
(Table 1). Thus, these data suggest that, during HIV-1
infection, CD1c is downregulated and cholesterol pro-
duction is increased. To rationalize why CD1c/CD1d
modulation is not more significantly enhanced during
HIV-1 infection and understand the role cholesterol pro-
duction may play in CD1c/CD1d expression during
infection, we blocked cholesterol production in the HIV-
1-infected cells by incubating the cells with 10 μM
simvastatin, an enzyme that inhibits the cholesterol bio-
synthesis pathway. We measured a dramatic decrease in
CD1c and CD1d expression in the presence of the in-
hibitor (Figure 3B), with CD1c expression decreasing by
17% compared to the HIV infected, untreated controls.
Simvastatin treatment alone had minimal (less than 1%
modulation) effects on CD1c expression (data not shown).
These data suggest that cholesterol production duringHIV-1 infection may aid in preventing further decreases
in CD1c and CD1d expression.
The effect of CD1c modulation and increased lipid synthesis
by HIV-1 infection on the CD1c-restricted T-cell response
Because an increased production of cholesterol resulted
in increased stimulation of CD1c-restricted T cells, and
HIV-1 infection induced the downregulation of CD1c
expression, we hypothesized that the HIV-1-mediated
downregulation of CD1c and elevated cholesterol pro-
duction would counteract each other and lead to the
overall level of the CD1c-restricted T-cell response. To
test this, we cultured HIV-1-infected Jurkat cells with
CD1c-restricted T cells and measured IFN-γ production
by the CD1c-restricted T cells. Compared to uninfected
controls, the HIV-1 infected cells showed a decreased
capacity to activate CD1c-restricted T cells (Figure 6A).
Thus, the decrease in CD1c expression during HIV-1 in-
fection appears to affect the ability of CD1c-restricted
T cells to recognize infected cells. This decrease in the
CD1c-restricted T-cell response was even more pro-
nounced in the presence of the cholesterol inhibitor sim-
vastatin, where CD1c expression was further decreased.
Anti-HIV-1 activity by CD1c-restricted T cells during
HIV-1 infection
The HIV-1-mediated decrease in CD1c expression and
the subsequent decrease in IFN-γ secretion by CD1c-
restricted T cells suggested that HIV-1 downregulates
CD1c in an effort to evade the host immune response.
To test this, we cultured HIV-1-infected cells with
CD1c-restricted T cells for 24 hours and measured viral
protein p24 production. In the presence of CD1c-
restricted T cells, less viral p24 was produced than by
infected cells alone (Figure 6B). Thus, while the HIV-1-
mediated decrease in CD1c expression appears to be an
immune evasion mechanism used by the virus to decrease
the CD1c-restricted T-cell reactivity, these attempts ap-
pear to be ineffective for suppressing the anti-viral re-
sponse mediated by the CD1c-restricted T cells.
Effect of HIV-1 infection on CD1c/CD1d expression by
primary cells and the subsequent CD1c-restricted primary
T-cell response
For the previous studies, we used Jurkat cells and CD1c-
restricted T cells that were stimulated for several weeks
prior to use. Both cell lines are not ideal as a physio-
logical model. Thus, we assessed CD1c and CD1d ex-
pression and endogenous lipid reactivity in primary cells.
First, peripheral blood mononuclear cells (PBMCs) iso-
lated from healthy donors were stimulated with 0.5 μg/ml
phytohaemagglutinin (PHA) for several days and infected
with HIV-1 IIIb, as described in the methods section. The
levels of CD1c and CD1d expression were measured
Figure 4 Vpu, but not Nef, plays a role in CD1c/CD1d modulation. Jurkat cells were infected with wild-type (WT), delta Vpu (ΔVpu), or delta
Nef (ΔNef) NL4-3 viruses for 2 days (A) or 10 days (B). The expression levels of CD1c and CD1d were then determioned by FACS and expressed
as Mean Fluorescence Intensity (MFI). Data represent results from one of three independent experiments. (C) HIV-1 RNA copy number at each
time point (2 days and 10 days post-infection) was determined by qPCR. HIV-1 RNA copy number was normalized based on the copy number of
GAPDH. Data represent results from one of three independent experiments.
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cells, there was a decrease in CD1c and CD1d expression
on the HIV-infected cells compared to the uninfected
controls. However, unlike the Jurkat cells, this decrease
was not significant (Figure 7).
We next sought to determine whether endogenous
lipid-reactive, CD1c-restricted T cells are present in the
peripheral blood. When we stimulated naïve T cells with
PC-loaded HeLa-CD1c cells, we found that 1.7% of these
naïve cells produced high levels of intracellular IFN-γFigure 5 Vpu-dependent CD1c and CD1d down-modulation. Jurkat ce
expressing vectors and CD1c and CD1d expression was checked after 24 h
expression (MFI) of untransfected and transfected cells as determined by F(Figure 8). This suggests that endogenous lipid-reactive
T cells do circulate at low levels in the periphery and
therefore may contribute to anti-HIV-1 immunity during
natural infection.
Discussion
One limitation of anti-HIV immunity is the inability of
the MHC-restricted immune response to keep up with
the antigenic variability of the virus. The CD1s are MHC-
like molecules that present lipid antigens to the immunells were transfected with full-length HIV (WT) or Vpu-only (vpu)
ours of transfection. Results correspond to the level of CD1c and CD1d
ACS.
Figure 6 HIV-1 infected cells have decreased capacity to induce IFN-γ secretion by CD1c-restricted T cells. (A) Jurkat cells were either
mock or HIV-1 IIIb infected with or without 10 μM simvastatin for 10 days. The cells were then used to stimulate CD1c-restricted T cells for
24 hours. Supernatants were collected and subjected to IFN-γ ELISA. (B) HIV-infected cells were cultured with or without CD1c-restricted T cells
overnight, and p24 was subsequently measured in supernatants. These data represent results from one of three independent experiments.
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tation of lipids may serve as a less variable antigen presen-
tation model. This could help initiate the immune
response before a peptide-restricted response occurs and/
or take part in enhancing the adaptive immune response
against infection.
In this study, we investigated the role of endogenous
lipid presentation during HIV infection. HIV relies heavily
on cholesterol for viral production, and in the absence of
cholesterol HIV production is impaired [28]. Data suggest
that HIV induces the upregulation of several enzymes
involved in the cholesterol biosynthesis pathway [29,30]
and the synthesis of cholesterol de novo within theFigure 7 HIV modulates CD1c/CD1d expression on primary
cells. Peripheral blood mononuclear cells (PBMCs) from healthy
donors were isolated, activated with phytohaemagglutinin (PHA),
and mock or HIV-1 IIIb infected for 10 days. The expression levels of
CD1c and CD1d were measured by FACS. The levels of CD1c/CD1d
expression were normalized using uninfected, treated controls and
plotted as % modulation from controls. Data represent results from
one of three independent experiments.infected cell [29]. We first assessed whether increased
cholesterol synthesis led to an increase in the levels of
CD1c and CD1d expression on the cell surface. When
Jurkat cells were cultured in the presence of mevalonate, a
cholesterol precursor known to increase the production of
newly synthesized cholesterol [31], we found that the
levels of CD1c and CD1d expression were not increased,
but instead maintained, suggesting that cholesterol pro-
duction may not play a role in upregulating CD1c/CD1d
expression. Rather, it appears that increased lipid produc-
tion helps to maintain CD1c/CD1d expression on the cell
surface. This hypothesis was supported by our finding that
treatment of HIV-infected cells with the cholesterol in-
hibitor simvastatin further decreased CD1c/CD1d expres-
sion, suggesting that HIV’s dual function in CD1c/CD1dFigure 8 Endogenous lipid reactive T cells circulate at low
levels in the periphery. Naïve T cells were stimulated with
PC-loaded HeLa-CD1c cells overnight. After gating the CD8+
population, intracellular IFN-γ was assessed by FACS. A solid black
line, a solid grey line, and a dashed line indicate PC-loaded, isotype
control, and unloaded, respectively. Data represent results from one
of three independent experiments.
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counteract each other resulting in limited downregulation
of CD1c and CD1d molecules from the cell surface.
Similar to what has been shown [23-27], we found that
like CD1d, CD1c is downregulated during HIV infection.
Contrary to some studies [23,24] and in agreement to
one recent study [26], we found that CD1d modulation
is Nef-independent. Importantly, the length of the infec-
tion may be a factor, as the two studies showing conflicting
results to ours assessed CD1d expression after 12 hours of
infection, but ours and the other study [26] assessed CD1d
modulation more than 2 days post-infection. Furthermore,
under these experimental conditions, we found that the
downregulation of CD1c and CD1d expression was Vpu-
dependent, which is similar to one study that showed
Vpu-dependent CD1d downregulation [27]. Finally, we
were able to confirm that Vpu itself is sufficient to down-
regulated both CD1c and CD1d by transfection experi-
ments. Nevertheless, further work is needed to fully
understand how Vpu, Nef, or other viral proteins play a
role in modulating CD1c and CD1d expression during
HIV infection.
We found that CD1c modulation affected the stimula-
tion of CD1c-restricted T cells, and this capacity to
stimulate CD1c-restricted T cells was further decreased
when CD1c expression was more significantly down-
regulated. This suggested that HIV intentionally down-
regulated CD1c molecules in an effort to reduce the
amount of IFN-γ secreted by CD1c-restricted T cells.
However, these attempts were not entirely effective, as
the lowered IFN-γ released in the presence of lowered
CD1c expression was still able to significantly reduce
viral production. This raises the question whether the
composition of endogenous lipids being presented drives
the CD1c-restricted T-cell response. This issue will need
to be clarified and resolved in a future study.
Our findings are the first to describe endogenous lipid
presentation and the functions of CD1c-restricted T cells
during HIV-1 infection. Recent data have shown that
HIV-1 Nef impairs cholesterol efflux from macrophages
[32]. Because of the HIV-1-mediated increase in choles-
terol production [29,30], even more cholesterol may be
sequestered within the cell. Thus, our data showing
CD1c downregulation during HIV-1 infection may indi-
cate one of the HIV-1 immune evasion mechanisms.
However, despite the HIV-1-mediated decrease in CD1c
expression, the attempts made by HIV-1 to decrease
CD1c-restricted T-cell activity were ineffective at com-
pletely suppressing the antiviral response. Taken to-
gether with our finding that the concurrent cholesterol
production induced by HIV-1 virus decreased the extent
of CD1c modulation, these data may be useful for
exploiting the maintained CD1c levels expressed during
HIV-1 infection.Conclusions
We found that HIV-1 infection induced the downregulation
of CD1c and CD1d expression through a Vpu-dependent,
Nef-independent mechanism, and the concomitant HIV-1-
induced production of host cholesterol decreased the extent
of CD1c and CD1d modulation. These two conflicting
HIV-1-mediated actions toward CD1c expression appear to
minimize the modulation of CD1c expression, thus leading
the host to maintain a CD1c-restricted T-cell response
against HIV-1.
Methods
Antibodies, cells, plasmids and viruses
Anti-CD1c antibody was purchased from Ancell (Bayport,
MN) and Biolegend (San Diego, CA). Monoclonal anti-
bodies against CD1d and HLA-A, B, and C were purchased
from BD Biosciences (San Diego, CA). The anti-human
IFN-γ antibody was purchased from Abcam (Cambridge,
MA). The human Jurkat cell line was obtained from ATCC
(Manassas, VA). Cells were cultured in complete RPMI
(CRPMI) medium consisting of RPMI 1640 containing
10% fetal calf serum (FCS), penicillin (50 U/ml), strepto-
mycin (50 μg/ml), 2 mM L-glutamine, 1.5 g/L sodium
bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM
sodium pyruvate. The cells were incubated in 5% CO2 at
37°C. HIV-1 IIIB was obtained from the National Institutes
of Health AIDS Research and Reference Reagent Program.
A WT plasmid encoding an entire HIV-1 sequence and a
PCR3.1 plasmid encoding only HIV-1 Vpu under the
CMV promoter were provided by Dr. Paul Bieniasz (Aaron
Diamond AIDS Research Center and Rockefeller Univer-
sity). HIV-1 NL4-3 delta Nef (ΔNef), HIV-1 delta Vpu
(ΔVpu) and WT viruses were kindly provided by Dr. Derya
Unutmaz (New York University School of Medicine),
Dr. Paul Bieniasz and Dr. Hiroshi Mori (Aaron Diamond
AIDS Research Center), respectively.
Endogenous lipids and other compounds
PC was purchased from Avanti Polar Lipids, Inc. (Alabaster,
AL). Mevalonate and simvastatin were purchased from
Sigma Aldrich (St. Louis, MO).
Transfection and infection of cells
As for the transfection, Jurkat cells were resuspended to
2 x 105 cells/ml in CRPMI medium and placed in a 12-
well plate prior to the transfection in a final volume of
1 ml per well. Transfection was performed using plasmid
encoding for GFP and the full-length HIV genome (WT)
or PCR3.1 vector encoding only Vpu of HIV-1. One μg
of DNA was diluted in 200 μl of Optimem serum free
media and incubated at room temperature for 15 min-
utes. After the incubation, 4 μl of Lipofectamine (Invi-
trogen) was added to the diluted DNA and incubated for
25 more minutes. The DNA-Lipofectamine complex was
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at 37°C with 5% CO2. After the incubation, cells were
harvested and checked for the expression of CD1c and
CD1d by a flow cytometric analysis. As for the infection,
2 x 106 Jurkat cells in 10 ml CRPMI were incubated with
virus (50TCID50) for 2 hours in 10-ml cell culture flasks
with gentle mixing every 15–30 minutes. The cells were
then incubated for the appropriate number of days at
37°C with 5% CO2.
Assessment of viral load by quantitative RT-PCR
After isolating total RNA from Jurkat cells infected with
corresponding HIV-1 viruses using RNAzol reagent
(Invitrogen), the RNA was used for RT-PCR reactions.
Ten-fold serial dilutions of plasmid containing the frag-
ment of the HIV-1 genome, ranging from 1 to 107 HIV-
1 copies per tube, were used to construct the HIV-1
RNA calibration curve. Ten-fold serial dilutions of plas-
mid containing the fragment of the human GAPDH
gene, ranging from 1 to 107 copies per tube, were used
to construct the GAPDH calibration curve. The number
of RNA copies used in the reaction was then normalized
based on the number of GAPDH copies. The quantitative
PCR performed with primers and a probe specific for
HIV-1 gag were; Forward primer; 50ATC AAG CAG CCA
TGC AAA TGT T30(578–599); Reverse primer; 50CTG
AAG GGT ACT AGT AGT TCC TGC TAT ATC30(722–
752), and Probe; 50FAM-ACC ATC AAT GAG GAA GCT
GCA GAA TGG GA-TAMRA30(607–636). GAPDH
quantitative PCR was performed with Forward primer;
50GAA GAT GGT GAT GGG ATT TC30, Reverse primer;
50GAA GGT GAA GGT CGG AGT C30, and Probe;
50VIC-CAA GCT TCC CGT TCT CAG CC-TAMRA30.
Assessment of CD1c/CD1d expression by a flow
cytometric analysis
Jurkat cells were harvested and stained for CD1c/CD1d
expression for 45 minutes on ice with APC-Cy7-labeled
anti-human CD1c antibody (Biolegend) and with PE-
labeled anti-human CD1d antibody (BD Biosciences),
according to the manufacturer’s instructions. The cells
were then washed twice in FACS buffer containing 1×
phosphate buffered saline, 2% fetal bovine serum, and
fixed in 1% paraformaldehyde. The Mean Fluorescence
Intensity (MFI) of both CD1c and CD1d on the GFP-
positive Jurkat cells was evaluated on the transfected
cells and compared to that on the untransfected con-
trols. Samples were acquired and analyzed using DIVA
software on a LSR II (BD, San Jose, CA, USA).
Generation of CD1c-restricted T cells
To generate the CD1c-restricted T cells, CD14+ cells
were isolated from PBMCs, and immature dendritic cells
(iDCs) were generated from the CD14+ cells after a 3-day incubation in the presence of 300 U/ml granulocyte-
macrophage colony-stimulating factor and 100 U/ml
interleukin (IL)-4. The iDCs were treated with mitomycin
C (50 μg/ml) for 1 hour followed by four washes with
culture media. The iDCs were preloaded with PC for
1 hour followed by the addition of the isolated T cells. Six
days later, 10 U/ml IL-2 was added, and 30 U/ml IL-2 was
added 3 days later or as needed. The cells were cultured
for a total of 15 days, re-stimulated for an additional 7–
10 days, tested for functionality, and used in experiments.
Assessment of the CD1c-restricted T-cell response
HeLa cells were transfected with expression vectors en-
coding CD1c and CD1d glycoproteins (kindly provided
by Dr. Shiratsuchi at Aaron Diamond AIDS Research
Center) using Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instruc-
tions. These HeLa-CD1c cells were then loaded with PC
(50 μg/ml) and used to stimulate the T cells overnight.
The next day, supernatants were collected, and IFN-γ
levels were assessed by enzyme-linked immunosorbent
assay (ELISA). For the experiments, CD1-restricted T
cells (5 × 105) were co-cultured with 5 × 105 Jurkat cells,
which were either pre-loaded for 1 hour with the indi-
cated amounts of lipid, unloaded, or infected with HIV.
The cells were incubated with or without treatment
with an inducer or inhibitor of cholesterol synthesis, as
described. After culture for 24 hours, supernatants were
collected, and IFN-γ secretion was assessed by ELISA.
Where applicable, supernatants were also assessed for
p24 antigen production by ELISA according to the man-
ufacturer’s instructions (Beckman Coulter, Brea, CA).
Measurement of cholesterol production
Two million uninfected or HIV-1-infected cells were
lysed with 0.1% Triton X solution and used to assess
cholesterol production using the Amplex Red Choles-
terol Assay Kit (Molecular Probes, Eugene, OR) accord-
ing to the manufacturer’s instructions.
Expression of CD1c/CD1d molecules in activated
primary cells
PBMCs were isolated from healthy donors and stimulated
with 0.5 μg/ml PHA for 3 days. Two million of these cells
were then infected with HIV-1 IIIb, HIV-1 NL4-3, HIV-1
NL4-3 ΔNef, or HIV-1 ΔVpu, as described above, and cul-
tured for 2 or 10 days. The level of CD1c/CD1d expres-
sion was then assessed on days 2 or 10 post-infection, as
described above.
Assessment of the frequency of PC-reactive CD1c-restricted
T cells among PBMCs
T cells were isolated from PBMCs from healthy donors
and stimulated with HeLa-CD1c cells that were preloaded
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and the cells were cultured for an additional 16 hours.
The next day the cells were gated for the CD8 positive
population and stained for intracellular IFN-γ, as assessed
by a flow cytometric analysis.
Statistical analysis
The Student’s t-test was used to compare differences among
the different experimental conditions tested.
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